Exploring the Role of PARP Inhibitors in Metastatic Breast Cancer

This chapter delves into the utilization of PARP inhibitors in metastatic breast cancer, addressing their efficacy in different subtypes like triple-negative and ER-positive disease. The speakers discuss treatment strategies, tolerability issues, and share a case study of a patient benefiting from PARP inhibitor therapy post-genetic testing. Emphasis is placed on the importance of genetic testing and considering various patient cohorts for PARP inhibition.